Exploring the connection between COVID-19 and diabetes
Dr Brittany Busse discusses why COVID-19 can influence the onset of diabetes and how this could shape the development of therapeutics.
List view / Grid view
Dr Brittany Busse discusses why COVID-19 can influence the onset of diabetes and how this could shape the development of therapeutics.
Researchers have used fragment screening alongside computational docking to reveal 20 hit antiviral compounds against SARS-CoV-2.
Induced pluripotent stem cells (iPSC) intestinal organoids have been created to duplicate SARS-CoV-2, enabling drug testing.
Dr Praveen Prathapan explains why broad-spectrum therapeutics need to be identified to provide a safety net against pandemics, including COVID-19.
Using cryo-electron microscopy, researchers have shown that the Spike (S) protein on cells exposed to the AstraZeneca vaccine is highly similar to the SARS-CoV-2 S protein.
A model of the SARS-CoV-2 Spike protein surface has uncovered vulnerabilities that researchers say could inform the development of COVID-19 vaccines.
Using a high-brilliance X-ray lightsource and protein crystallography, researchers have identified two drugs that inhibit the main protease of SARS-CoV-2.
With the ongoing COVID-19 pandemic, new treatments continue to be urgently needed. One potential solution is antibody therapeutics, which can be used to neutralise the coronavirus and provide future immunity to patients. Here, Dr Laura Walker from Adagio Therapeutics discusses how antibodies can be used in the fight against Severe…
Recent years have seen an increase in the development of biomaterial and nanoparticle-based vaccine formulations. Sushma Kumari, Sonal Asthana and Kaushik Chatterjee from the Department of Materials Engineering at the Indian Institute of Science discuss why these materials have such high potential in the fight against infectious diseases.
Within this ebook, find articles on how a lead bNAb candidate was identified to combat COVID-19 and why antibodies could present the answer to HIV treatment and vaccines.
A drug called topotecan (TPT) was administered to mice up to four days after COVID-19 infection, reducing inflammation and morbidity.
Researchers have revealed that T cells in blood samples from people who recovered from COVID-19 responded to SARS-CoV-2 variants.
The length of time between the administration of a COVID-19 vaccine and evidence of a robust immune response to Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) means that treatments are still required. In this article, Sheraz Gul and Alp Tegin Sahin explore the various therapeutic targets that have been identified…
Researchers have used imaging mass cytometry to analyse the cellular landscape of diseased lung tissue in severe COVID-19, revealing insights into the disease.
Sheraz Gul reviews where we are a year into the COVID-19 pandemic and the treatment options currently available. He also highlights the potential opportunities and challenges posed by SARS-CoV-2 vaccines.